drugset / Trial / NCT06894719

Oral Tranexamic Acid After Total Knee Arthroplasty

NCT06894719

Phase 4 Not yet recruiting 351 enrolled Rush University Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively. Hypothesis: Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.

Timeline

Start
2026-06-01
Primary completion
2026-12-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 1.95 g Oral

Indications

No indication recorded.